,
6 min read
Introduction
Under the EU IVDR 2017/746, performance evidence does not end at market entry. Regulators expect manufacturers to continuously confirm that an In Vitro Diagnostic (IVD) performs as intended in real-world use, across diverse populations and evolving clinical practice. This expectation is formally established through the Post-Market Surveillance (PMS) system requirements outlined in IVDR Article 78 and is operationalized through Post-Market Surveillance (PMS), Post-Market Performance Follow-up (PMPF), and, where applicable, Periodic Safety Update Reports (PSURs).
Together, these elements form a lifecycle evidence system that sustains confidence in performance claims over time. When designed and executed effectively, PMS, PMPF, and PSURs reinforce IVDR Performance Evaluation by ensuring that pre-market assumptions remain valid and that emerging risks or trends are identified and addressed proactively.
The Role of Post-Market Evidence Under IVDR
IVDR places explicit emphasis on post-market learning because pre-market studies cannot fully capture real-world variability. Differences in patient populations, specimen handling, operator behaviour, and clinical workflows can all influence performance once an IVD is widely used.
Post-market evidence serves several critical purposes. It confirms that clinical performance observed during development persists in routine use, identifies previously unrecognised limitations, and provides early warning of performance drift or emerging risks. This evidence feeds directly back into the ongoing Performance Evaluation, ensuring that the IVDR Performance Evaluation Report (PER) remains current and defensible.
Regulatory expectations for these processes are articulated in the IVDR and clarified in the European Commission’s MDCG endorsed guidance documents, which Notified Bodies frequently refer to during assessments.
Post-Market Surveillance (PMS): The Foundation of Lifecycle Monitoring
Post-Market Surveillance is the systematic collection and analysis of data on device performance after it is placed on the market. Under IVDR, PMS is not limited to vigilance reporting; it is an active process designed to detect trends, confirm performance, and inform risk–benefit reassessment.
PMS activities may include complaint analysis, trend reporting, vigilance data, user feedback, and ongoing literature surveillance. The key requirement is that PMS is planned, proportionate to risk, and capable of identifying meaningful signals rather than simply accumulating data.
A well-designed PMS system strengthens the defensibility of IVDR Performance Evaluation by demonstrating that manufacturers maintain active oversight of real-world performance and respond appropriately to new information.
Post-Market Performance Follow-up (PMPF): Targeted Evidence Generation
Post-Market Performance Follow-up (PMPF) under EU IVDR is a focused subset of PMS that addresses specific performance questions or residual uncertainties identified during pre-market evaluation. While not every IVD requires extensive PMPF, IVDR sets a high bar for justifying its absence, particularly for higher-risk or clinically impactful devices.
PMPF activities may include prospective observational studies, participation in registries, targeted follow-up of specific patient groups, or structured analysis of real-world performance metrics. The objective is not to repeat pre-market studies, but to generate evidence that confirms performance in routine clinical use or addresses gaps identified in the Performance Evaluation Report.
Effective PMPF planning begins during Performance Evaluation, where uncertainties are identified explicitly and translated into targeted post-market questions. This alignment ensures that PMPF data is meaningful, review-ready, and directly relevant to maintaining evidence sufficiency.
PSUR: Periodic Reassessment of Risk and Performance
For certain IVD risk classes, IVDR requires the preparation of Periodic Safety Update Reports. PSURs provide a structured summary of post-market data, including performance trends, vigilance outcomes, and risk–benefit reassessment.
While PSURs are often discussed in safety terms, they are also an important artefact of performance evidence. They demonstrate that post-market findings are systematically reviewed, that conclusions are updated when necessary, and that corrective or preventive actions are appropriately implemented.
When integrated effectively, PSURs reinforce the lifecycle logic of IVDR performance evaluation by showing how post-market insights influence ongoing evidence assessment and documentation.
Traceability: Connecting PMS, PMPF, and the Performance Evaluation Report
One of the most important characteristics of a robust post-market system is traceability. Notified Bodies increasingly expect manufacturers to show how post-market findings map back to performance assumptions, claims, and residual risks identified during pre-market evaluation.
Traceability ensures that:
- PMS data informs whether clinical performance remains consistent with claims
- PMPF activities address defined evidence gaps
- PSUR conclusions feed into updates of the Performance Evaluation Report
- Evidence sufficiency is reassessed systematically rather than reactively
This traceable lifecycle approach aligns with broader clinical and performance evaluation practices, in which governance and evidence flow are intentionally designed rather than managed as an ad hoc process.
Integrating Post-Market Evidence into Performance Evaluation
Post-market evidence gains regulatory value only when it is actively integrated into performance evaluation. This means updating the Performance Evaluation Report when new data materially affects performance conclusions, risk–benefit assessments or claim justification.
Manufacturers that treat PMS and PMPF as disconnected compliance activities often struggle during conformity assessment or surveillance audits. In contrast, those that integrate post-market evidence into a unified evaluation framework tend to demonstrate stronger control, clearer reasoning, and greater regulatory confidence.
This integration is particularly important when real-world data reveals trends that were not fully captured in pre-market studies. Addressing such findings transparently rather than defensively strengthens long-term evidence credibility.
Common Challenges and How to Address Them
A frequent challenge under IVDR is over-collection of post-market data without a clear analytical purpose. Data that is not evaluated meaningfully does little to support performance evaluation and may even obscure important signals.
Another challenge is insufficient linkage between post-market findings and performance documentation. Without clear traceability, reviewers may question whether post-market learning genuinely informs ongoing evaluation.
Both challenges can be mitigated by designing PMS and PMPF activities that are directly linked to performance claims, identified uncertainties, and lifecycle evidence objectives from the outset.
Conclusion
PMS, PMPF, and PSUR are not peripheral compliance obligations under the EU IVDR; they are central components of a lifecycle evidence system that sustains confidence in IVD performance. Together, they ensure that performance assumptions are confirmed in real-world use and that emerging risks or trends are identified early.
When integrated effectively into Performance Evaluation, post-market processes reinforce the credibility of the Performance Evaluation Report under IVDR and demonstrate ongoing control over performance evidence. By treating post-market learning as an extension of pre-market evaluation rather than a separate obligation, manufacturers can build a robust, traceable evidence system that supports long-term regulatory compliance and trust in diagnostic results.
How Freyr Supports IVDR PMS, PMPF, and PSUR
Effective IVDR post-market surveillance requires a structured, performance-driven approach to real-world evidence generation and lifecycle oversight. Freyr supports IVD manufacturers in developing IVDR-compliant PMS and PMPF strategies, aligning post-market data collection with performance evaluation requirements, and ensuring traceability across lifecycle documentation.
Freyr’s experts assist with PMS planning, PMPF design, PSUR preparation, post-market data integration, and performance evaluation report updates. For support with IVDR PMS, PMPF, PSUR, or lifecycle performance evaluation strategy, speak to a Freyr expert to discuss your regulatory challenges.
